文献速递肾癌与肾肿瘤

肾细胞癌转移灶切除术后的并发症:一项基于人群的评估

Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment.
PubMed 文献 · Eur Urol · 2017-03-27

研究基于美国全国住院患者样本数据库(2000-2011年)纳入45 279例转移性肾细胞癌患者,其中1102例接受转移灶切除术。总体并发症发生率为45.7%,主要并发症(Clavien III-V级)占27.5%。肝脏病灶切除与其他部位相比总体并发症风险显著升高(比值比2.59,95%置信区间1.84-3.62,p<0.001)。

要点

  • 转移灶切除术后总体并发症发生率为45.7%,主要并发症(Clavien III-V级)占27.5%。
  • 肝脏病灶切除与其他部位相比总体并发症风险显著升高(比值比2.59,95%置信区间1.84-3.62,p<0.001)。
  • 转移灶切除术仍为寡转移性肾细胞癌的潜在治疗选择,但并发症发生率不可忽视,需仔细筛选患者。

核心结论

  • 转移灶切除术仍是寡转移性肾细胞癌的潜在治疗选择,但相关并发症发生率不可忽视,因此需要仔细筛选患者。

研究设计与样本

  • 利用美国全国住院患者样本数据库(2000-2011年)识别45 279例转移性肾细胞癌患者,其中1102例接受转移灶切除术,描述住院期间并发症。

主要发现

  • 转移部位分别为肺52%、骨29%、肝19%、淋巴结14%、肾上腺11%和脑3.4%。
  • 总体并发症发生率为45.7%,主要并发症(Clavien III-V级)占27.5%。
  • 肝脏病灶切除与其他任何部位相比总体并发症风险显著升高(比值比2.59,95%置信区间1.84-3.62,p<0.001)。

临床怎么用

  • 原文结论指出转移灶切除术仍是寡转移性肾细胞癌的潜在治疗选择,但并发症不可忽视,需仔细筛选患者;结果可能有助于术前咨询。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Metastasectomy has long been considered a valid treatment option for patients with oligometastatic renal cell carcinoma (oligo-mRCC). However, the literature on complications in this setting is scarce. Our objective was to describe in-hospital complications after metastasectomy in a contemporary cohort of patients with mRCC. Using the National Inpatient Sample database (2000-2011), 45 279 mRCC patients were identified. Of those, 1102 underwent metastasectomies. The metastatic sites were the lungs, bone, liver, lymph nodes, adrenal glands, and brain in, respectively, 52%, 29%, 19%, 14%, 11%, and 3.4% of patients. The overall complication rate was 45.7%. Major complications (Clavien III-V) constituted 27.5%. Resections of hepatic lesions were significantly associated with higher odds of overall complications compared with any other site (odds ratio 2.59, 95% confidence interval 1.84-3.62, p<0.001). While metastasectomy remains a potential treatment option in RCC with oligometastatic disease, the associated complication rates are non-negligible; therefore, careful patient selection is warranted. PATIENT SUMMARY: We studied outcomes of patients with metastatic kidney cancer treated with metastasectomy. While metastasectomy is a treatment option for metastatic renal cell carcinoma, complications are not insignificant and our results may guide preoperative counseling.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Meyer CP, Sun M, Karam JA, et al. Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment. Eur Urol. 2017. PMID: 28359734. doi:10.1016/j.eururo.2017.03.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。